Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
FBR Capital Remains Bullish on Advaxis (ADXS) Following Conference Call About FDA IND Clinical Hold
October 7, 2015 7:49 AM EDTFBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast. The call was to discuss the announcement that its Investigational New Drug (IND) application for axalimogene filolisbac (AF) was placed on clinical hold by the FDA, affecting four clinical trials with AF in cervical cancer.
Analyst Vernon Bernardino commented, "Advaxis, after market... More
